AAADV Workshop Foundation Unveils Program for 2026 Workshop, Convening the Architects of Modern Oncology Drug Regulation

November 5–6, 2026
North Bethesda Marriott Hotel & Conference Center Hybrid Meeting (In-Person & Virtual)

Two-day program on November 5–6, 2026 will bring together five landmark FDA and NIH leaders, six plenary sessions, and a marquee fireside chat on the future of oncology drug development

BETHESDA, Md. — The AAADV Workshop Foundation today released the official program agenda for the 2026 Accelerating Anticancer Agent Development and Validation (AAADV) Workshop, to be held November 5–6, 2026, at the North Bethesda Marriott Hotel & Conference Center in Bethesda, Maryland, with in-person and virtual participation. Now in its third decade, the AAADV Workshop remains one of the oncology community’s most influential forums for clinical and translational investigators, regulators, industry leaders, biostatisticians, and patient advocates working to advance the science, methodology, and regulatory framework of cancer drug development.
The 2026 program reflects the workshop’s evolution into a truly global, multi-stakeholder venue. Over two days, attendees will engage with six plenary sessions, three keynote addresses, and a headline fireside chat — each designed to tackle the most consequential questions facing oncology drug development today: how to design rigorous multi-regional trials, how to weigh benefit and risk, how to optimize dose for novel modalities, and how to learn from both successes and failures in the regulatory arena.